EUVIMEDEUVIMED entdecken
Open Access

Transfusion requirements in recipients of plasma units from blood donors with recent SARS ‐ CoV ‐2 infection

Nareg H Roubinian iD, Colleen Plimier, Bryan R Spencer iD, Marjorie Bravo iD, Brian Custer iD, Angelo D'Alessandro, Steve Kleinman, Philip J Norris iD, Michael P Busch, NHLBI Recipient Epidemiology and Donor Evaluation Study‐IV‐P (REDS‐IV)

Transfusion · 2026

DOI: 10.1111/trf.70118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2026. Verfasst von Nareg H Roubinian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente Northern California Division of Research, Pleasanton, California, USA. Hauptthemen laut MEDLINE: COVID-19, Blood Donors, SARS-CoV-2, Blood Component Transfusion. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

SARS‐CoV‐2 infection is associated with hypercoagulability in patients with Coronavirus disease (COVID‐19). We used a vein‐to‐vein database to examine the impact of transfusion of plasma units from blood donors with recent SARS‐CoV‐2 infection. Study Design and Methods We linked donor SARS‐CoV‐2 serology data with plasma transfusions occurring between 6/1/2020 and 3/31/2022. Using multivariable regression, we examined changes in the international normalized ratio (INR) and subsequent transfusion requirements following plasma transfusion relative to the timing of donor SARS‐CoV‐2 nucleocapsid antibody (anti‐N Ab) positivity.

Results

We identified 2350 adults who received 5397 plasma units with donor SARS‐CoV‐2 serology data as part of 3721 plasma transfusion events. 8.1% (436/5397) of plasma units were from anti‐N Ab positive donors, and median time from index seropositivity to donation was 89 days (interquartile range [IQR] 0–210). In recipients of plasma units from recently SARS‐CoV‐2 infected donors (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Blood DonorsSARS-CoV-2Blood Component TransfusionHumansFemaleMiddle AgedAdultMaleBlood DonationInternational Normalized RatioPlasmaAntibodies, Viral

Substanzen

Antibodies, Viral

Autor:innen und Institutionen

  • Kaiser Permanente Northern California Division of Research, Pleasanton, California, USA.
  • Vitalant Research Institute, San Francisco, California, USA.
  • University of California, San Francisco, San Francisco, California, USA.
  • American Red Cross, Scientific Affairs, Dedham, Massachusetts, USA.
  • Vitalant, Scottsdale, Arizona, USA.
  • University of Colorado, Aurora, Colorado, USA.

ORCID-Profile: Nareg H Roubinian, Bryan R Spencer, Marjorie Bravo, Brian Custer, Philip J Norris

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Roubinian, N. H., Plimier, C., Spencer, B. R., Bravo, M., Custer, B., D'Alessandro, A., Kleinman, S., Norris, P. J., Busch, M. P., & NHLBI Recipient Epidemiology and Donor Evaluation Study‐IV‐P (REDS‐IV) (2026). Transfusion requirements in recipients of plasma units from blood donors with recent SARS ‐ CoV ‐2 infection. Transfusion. https://doi.org/10.1111/trf.70118

Vancouver

Roubinian NH, Plimier C, Spencer BR, Bravo M, Custer B, D'Alessandro A, et al. Transfusion requirements in recipients of plasma units from blood donors with recent SARS ‐ CoV ‐2 infection. Transfusion. 2026. doi:10.1111/trf.70118

BibTeX
@article{Roubinian2026,
  author = {Roubinian, Nareg H and Plimier, Colleen and Spencer, Bryan R and Bravo, Marjorie and Custer, Brian and D'Alessandro, Angelo and Kleinman, Steve and Norris, Philip J and Busch, Michael P and NHLBI Recipient Epidemiology and Donor Evaluation Study‐IV‐P (REDS‐IV), NHLBI Recipient Epidemiology and Donor Evaluation Study‐IV‐P (REDS‐IV)},
  title = {Transfusion requirements in recipients of plasma units from blood donors with recent SARS ‐ CoV ‐2 infection},
  journal = {Transfusion},
  year = {2026},
  doi = {10.1111/trf.70118}
}
Kostenlos starten →